Category: Insights

Pharmaceutical Investments: Making the Case for Better Intelligence

Market intelligence is especially critical to sound pharmaceutical investing Pharmaceutical investing is both challenging and potentially very rewarding, but it requires understanding trends in the industry, including which drugs are…
The post Pharmace…


A drug by any other name would work just as well — making sense of drug names

How are drugs named, and how do names aid in prescription and generic substitution? In William Shakespeare’s play Romeo and Juliet, Juliet uses the phrase “A rose by any other name…
The post A drug by any other name would work just as well — making sen…


Biosimilar Naming: Distinguishable or Disingenuous?

This is a guest post from Robert Yapundich, MD and Gregory Schimizzi, MD. Dr. Yapundich is a practicing neurologist in Hickory, North Carolina and a member of the Alliance for…
The post Biosimilar Naming: Distinguishable or Disingenuous? appeared first…


Download FDA Orange Book Archives

How to Order the FDA Orange Book Historical copies of the FDA Orange Book archives are very potent tools for scholarly research and for litigation support, but until now there…
The post Download FDA Orange Book Archives appeared first on DrugPatentWatc…


Value-based drug pricing makes sense, but is difficult to pull off

Dana Goldman, Anupam Jena, Posted with permission from STAT It’s hard not to like the notion of value-based pricing for prescription drugs. It aims to ensure that the prices we pay for…
The post Value-based drug pricing makes sense, but is difficult to…


The Cost Of A Cure: Patent Rights And Drug Prices

One of the hottest-button political issues of the day is high prescription drug costs. On one side of the debate are politicians and patient groups espousing a populist viewpoint seeking…
The post The Cost Of A Cure: Patent Rights And Drug Prices appea…


How a $37,000-a-year medicine sets a good model for drug pricing

Ed Silverman, Posted with permission from STAT Shortly before his company won the right last week to sell a new drug for severe eczema, Dr. Len Schleifer made a brash…
The post How a $37,000-a-year medicine sets a good model for drug pricing appeared f…


Q&A: Three big mistakes drug companies make in recruiting new employees

Rebecca Robbins, Posted with permission from STAT Plus When drug and device makers need a new chief medical officer or vice president, they often start by turning to executive recruiters. One…
The post Q&A: Three big mistakes drug companies make in rec…


As blockbuster drugs fizzle, biotech looks warily to the next big thing

Damian Garde, Posted with permission from STAT Has the age of the biotech blockbuster come to a close? Over the past year, a string of would-be best-sellers, expected to generate…
The post As blockbuster drugs fizzle, biotech looks warily to the next b…


Americans overspend $73bn on branded drugs

File this under ‘unintended consequences.’ A number of health care organizations are complaining that a final guideline the US Food and Drug Administration recently released for naming both biologic medicines…
The post Americans overspend $73bn on bran…


Do NOT follow this link or you will be banned from the site!